RT Journal Article
SR Electronic
T1 Non-invasive estimation of intracranial pressure by diffuse optics – a proof-of-concept study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.21.20109256
DO 10.1101/2020.05.21.20109256
A1 Fischer, Jonas B.
A1 Ghouse, Ameer
A1 Tagliabue, Susanna
A1 Maruccia, Federica
A1 Rey-Perez, Anna
A1 Báguena, Marcelino
A1 Cano, Paola
A1 Zucca, Riccardo
A1 Weigel, Udo M.
A1 Sahuquillo, Juan
A1 Poca, Maria A.
A1 Durduran, Turgut
YR 2020
UL http://medrxiv.org/content/early/2020/05/23/2020.05.21.20109256.abstract
AB Intracranial pressure (ICP) is an important parameter to monitor in several neuropathologies. However, because current clinically accepted methods are invasive, its monitoring is limited to patients in critical conditions. On the other side, there are other less critical conditions where ICP monitoring could still be useful, thus there is a need to develop non-invasive methods. We propose a new method to estimate ICP based on the analysis of the non-invasive measurement of pulsatile, microvascular cerebral blood flow with diffuse correlation spectroscopy. This is achieved by training a recurrent neural network using only the cerebral blood flow as the input. The method is validated using a 50% split sample method using the data from a proof-of-concept study. The study involved a population of infants (n=6) with external hydrocephalus (initially diagnosed as benign enlargement of subarachnoid spaces) as well as a population of adults (n=6) suffering from traumatic brain injury. The algorithm was applied to each cohort individually to obtain a model and an ICP estimate. In both diverse cohorts, the non-invasive estimation of ICP was achieved with an accuracy less than <4 mmHg and a negligible small bias. Furthermore, we have achieved a good correlation (Pearson’s correlation coefficient >0.9) and good concordance (Lin’s concordance correlation coefficient >0.9) in comparison to standard clinical, invasive ICP monitoring. This preliminary work paves the way for further investigations of this tool for the non-invasive, bed-side assessment of ICP.Competing Interest StatementTurgut Durduran is an inventor on relevant patents. ICFO has equity ownership in the spin-off company HemoPhotonics S.L. Potential financial conflicts of interest and objectivity of research have been monitored by ICFO's Knowledge & Technology Transfer Department. No financial conflicts of interest were identified. Udo Weigel is the CEO, has equity ownership in HemoPhotonics S.L. and Udo Weigel and Jonas Fischer are employees. Their role has been defined by the BitMap project and was reviewed by the European Commission. All other authors have no financial conflict of interests.Funding StatementThis work leading to the results was funded by the European Union’s Horizon 2020 project “BitMap: Brain injury and trauma monitoring using advanced photonics” (No. 675332); Fundació CELLEX Barcelona; Ministerio de Economía y Competitividad /FEDER (PHOTODEMENTIA, DPI2015-64358-C2-1-R); Instituto de Salud Carlos III / FEDER (MEDPHOTAGE, DTS16/00087 and PI18/00468); the “Severo Ochoa” Programme for Centers of Excellence in R&D (SEV-2015-0522); the Obra social “laCaixa” Foundation (LlumMedBcn); Institució CERCA, AGAUR-Generalitat (2017 SGR 1380); LASERLAB-EUROPE IV; KidsBrainIT (ERA-NET NEURON) and la Fundació La Marató de TV3 (201709.31 and 201724.31).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:PR(AMI)459/2017 ACU-AT-203/2012(3531)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available on request from the authors (JF, TD).